AbbVie's Allergan Aesthetics division has secured FDA approval for SKINVIVE by JUVÉDERM for improvement of neck appearance, marking the first filler indication specifically cleared for the neck in the U.S. market. The approval opens a new revenue stream in a category where practices have historically relied on off-label filler use, laser, or RF modalities.
Injectables
AbbVie Wins FDA Approval for SKINVIVE by JUVÉDERM for Neck — First Filler Indication in Category
Allergan Aesthetics' new neck-appearance indication expands the JUVÉDERM filler portfolio beyond face and lips.
First filler indication specifically cleared for the neck in the U.S. market.
SKINVIVE is formulated with JUVÉDERM's proprietary cross-linked hyaluronic acid and is designed for subdermal injection to address skin laxity and volume loss in the neck. This approval follows SKINVIVE's earlier clearance for cheek augmentation and sits within AbbVie's broader strategy to expand JUVÉDERM's clinical footprint beyond traditional facial zones. Practices will need to update consent forms and training protocols; the indication also creates an opportunity to bundle neck treatment with existing face/lip cases.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.